Spero Therapeutics Announces Pricing of Initial Public Offering
November 01 2017 - 6:00PM
Spero Therapeutics, Inc., a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and
commercializing novel treatments for multi-drug resistant bacterial
infections, today announced the pricing of its initial public
offering of 5,500,000 shares of its common stock at a public
offering price of $14.00 per share, before underwriting discounts
and commissions. Spero Therapeutics, Inc.’s shares are expected to
begin trading on The Nasdaq Global Select Market on November 2,
2017 under the symbol “SPRO.” All of the shares are being
offered by Spero Therapeutics, Inc. In addition, Spero
Therapeutics, Inc. has granted the underwriters a 30-day option to
purchase up to 825,000 additional common shares at the initial
public offering price. The offering is expected to close on
November 6, 2017, subject to the satisfaction of customary closing
conditions.
BofA Merrill Lynch, Cowen and Stifel are serving as joint
book-running managers for the proposed offering. Oppenheimer &
Co. is acting as a co-manager for the proposed offering.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission. The offering will be made only by means of a
prospectus. Copies of the final prospectus relating to this
offering, when available, may be obtained from BofA Merrill Lynch,
NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, or by email at
dg.prospectus_requests@baml.com; from Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, Attention: Prospectus Department, or by telephone at
(631) 274-2806; and from Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite
3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or
by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Spero
Spero Therapeutics is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and
commercializing novel treatments for multi-drug resistant bacterial
infections.
Spero Media and Investor Contact
Sharon KlahreDirector, Investor
Relations857-242-1547IR@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2023 to Apr 2024